Last reviewed · How we verify
NCT06024343
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
NA trial testing MPD Exposure, Repair or Reconstruction in Pancreatic Tumor, Benign in 230 participants. Completed in 31 August 2024.
30 May 2024
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 230 |
| Start date | 1 July 2019 |
| Primary completion | 30 May 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- MPD Exposure, Repair or Reconstruction
Conditions studied
- Pancreatic Tumor, Benign — all drugs for Pancreatic Tumor, Benign →
- Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →
- Solid Pseudopapillary Tumor of the Pancreas — all drugs for Solid Pseudopapillary Tumor of the Pancreas →
Sponsor
Fudan University
Who can join
Adults 18 to 75, any sex, with Pancreatic Tumor, Benign or Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the impact of concomitant main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Minimally invasive enucleation of pancreatic tumors: The main pancreatic duct is no longer a restricted area.
Li Z, Zhuo Q, Shi Y, Chen H, et al · · 2023 · cited 7× · PMID 38027678 · DOI 10.1016/j.heliyon.2023.e21917 -
Main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic enucleation: a long-term metabolic outcome from a prospective cohort study (CSPAC-MIEN-1).
Li Z, Shi Y, Zhuo Q, Liu M, et al · · 2025 · cited 1× · PMID 40679988 · DOI 10.1097/js9.0000000000003016
Verify or expand the search:
- PubMed search for NCT06024343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06024343 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06024343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing